Glucagon-like peptide-1 receptor agonists (GLP-1RAs) were initially developed for the treatment of type 2 diabetes mellitus and now have a key role in obesity management
While the clinical trials for drugs like semaglutide (Wegovy/Ozempic) and tirzepatide (Zepbound/Mounjaro) demonstrate that efficacy is dose-dependent (higher doses yield more significant results), they also confirm that the initial, lower doses of the medications still provide measurable benefits for appetite suppression and blood sugar control
There is no insurance requirement, and TrimRx accepts HSA and FSA funds along with buy-now-pay-later options like Affirm, Afterpay, and Klarna for people who want to spread out payments
When considering Tirzepatide for weight loss, it is essential to understand its role in the chronic management of obesity and diabetes, as well as setting realistic long-term goals and expectations
How to Use: Typically prescribed as a once-weekly injection given on the same day each week, with or without food
According to a Kaiser Family Foundation report, only ~13 Medicaid programs covered GLP-1 weight-loss indications as of late 2024 ( [24] ), and major insurers have at times dropped GLP-1 coverage for obesity after high spending ( [25] )
